ClinicalTrials.gg
TerminatedNCT03954314DEPOSITIONUpdated Oct 26, 2026Results posted

DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery

A Phase 3 interventional study of Tranexamic Acid in Bleeding, Surgical Blood Loss and Seizures, sponsored by Population Health Research Institute. Terminated at 16 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Primary conditionBlood Loss, SurgicalRegistry: HemorrhageReclassifiedWhy we changed it
Registry
Hemorrhage — the first condition term the registry derived for this study.
ClinicalTrials.gg
Blood Loss, Surgical
Why
  1. The study's listed conditions name Blood Loss, Surgical, a narrower term within Hemorrhage.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Population Health Research Institute · Phase 3, Interventional, and Prevention

How we know

Why this study was terminated
Upon the Data Safety Monitoring Board review of the interim analysis (75% of participants have finished their follow-up) on November 17, 2023, they made a recommendation to stop recruitment into the trial.
Updated Oct 26, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,242
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing Tranexamic Acid in Blood Loss, Surgical — 9 open to participants now, 9 under way, 4 of them phase 3. Tranexamic Acid · Blood Loss, Surgical.

Enrollment
Largest of 46
3,242 · median 98
Started
2019
with 5 others
Phase 3
9 of 46
4 open now
Registered
20th of 46
by date
Lead sponsor
2 of 46
Population Health Research Institute

Among the 46 studies testing Tranexamic Acid in Blood Loss, Surgical, this one has the largest enrollment, is one of 6 that started in 2019, is one of 9 in phase 3, and was the 20th registered.

Blood Loss, Surgical

213 studies on the registry are indexed under Blood Loss, Surgical; 40 are open to participants now.

Browse Blood Loss, Surgical studies →

Open to participants now

9 of the 46 studies testing Tranexamic Acid in Blood Loss, Surgical are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 27 Blood Loss, Surgical studies recruiting now, 10 (37%) set no upper age limit and 14 (52%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing Tranexamic Acid in Blood Loss, Surgical, or all of them as a file.
02

Study summary

The aim is to conduct a double-dummy multi-centre randomized controlled clinical trial of application of topical dose of tranexamic acid (TxA) versus the usual intravenous TxA in patients undergoing on-pump cardiac surgery.

Read the detailed description

Postoperative bleeding related to open cardiac surgery increases the rates of complications and mortality. It results from the blood thinners that are needed for use. Intravenous tranexamic acid (TxA) has become a mainstay in cardiac surgical procedures for decreasing bleeding and minimizing transfusion requirements. Although intravenous TxA is usually well tolerated, there is a well-known risk (1 to 4%) of postoperative seizures. This is due to the similarity between TxA and the brain tissues. The aim is to eliminate the risk of seizures but to maintain the protection against bleeding. When TxA is used directly on the tissues (topically) for other type of surgeries (joints), TxA is effective to reduce blood loss and transfusions. The aim is to prove that direct application of TxA on the heart can eliminate postoperative seizures and reduce the amount of blood transfusions in patients who have cardiac surgery.

03

Conditions studied

  • Bleeding
  • Surgical Blood Loss
  • Seizures

Browse trials for

Keywords

  • Tranexamic Acid
  • On-pump Cardiac Surgery
04

In context

Blood Loss, Surgical Reclassified

213 studies on the registry are indexed under Blood Loss, Surgical; 40 are open to participants now.

This study's enrollment of 3,242 is above the median of 80 across 160 interventional studies indexed under Blood Loss, Surgical.

Browse Blood Loss, Surgical studies →

Lead sponsor

Population Health Research Institute is the lead sponsor of 115 studies on the registry; 26 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Compared within Blood Loss, Surgical, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hemorrhage. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age
  2. Undergoing a cardiac surgical procedure (i.e. isolated coronary artery bypass graft (CABG), isolated single cardiac valve surgery or a combination of both or isolated ascending aorta replacement) with the use of cardiopulmonary bypass (CPB) and median sternotomy
  3. Provide written

Exclusion criteria

Exclusion Criteria:

  1. Allergy to tranexamic acid
  2. Undergoing minimally invasive surgery
  3. Fulfill any of the following transfusion risk factors (A-D):

    A. Emergency surgery B. History of bleeding disorder C. Inherited thromboembolic or hemorrhagic disease D. Infective endocarditis (active)

  4. History of previous cardiac surgery
  5. Estimated \<30 mL/min (CKD-EPI equation) or on dialysis
  6. Pre-operative > 170 g/L or \<110 g/L
  7. Pre-operative thrombocytopenia (\<50,000 per µL)
  8. Expected circulatory arrest
  9. Pregnancy or breast feeding
  10. Previously enrolled in the DEPOSITION trial
  11. Refusal of blood products
  12. Pericardiectomy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,242 participants (actual)

Study arms

  • Active comparator
    Topical Tranexamic Acid/Placebo

    Topical Tranexamic Acid 5g to 10g (50 to 100mL) or placebo. The topical will be poured into the pericardial and mediastinal cavities after protamine administration.

    Drug: Tranexamic Acid

  • Active comparator
    Intravenous Tranexamic Acid/Placebo

    Intravenous Tranexamic Acid 1 to 10g (10 to 100mL) or placebo administered intravenously at the induction of anesthesia as a bolus-infusion.

    Drug: Tranexamic Acid

Interventions

  • Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.

    Also known as: Cyklokapron

07

What researchers measure

Primary outcomes

  1. The Proportion of Patients Experiencing an In-hospital Seizure

    To determine in patients undergoing on-pump cardiac surgery, if topical tranexamic acid (intra-pericardial) is superior to the usual intravenous tranexamic acid administration for reducing the risk of in-hospital seizure.

    Time frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)

Secondary outcomes

  1. The Proportion of Patients In-hospital Who Receive Red Blood Cell Transfusions

    To determine in patients undergoing on-pump cardiac surgery, if topical tranexamic acid (intra-pericardial) compared with intravenous tranexamic acid administration is associated with a non-inferior risk of in-hospital red blood cell transfusion.

    Time frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)

Other outcomes

  1. Blood Product Transfusions

    Analyzed using an ANCOVA model. In such a model, bags of blood product will be included as a dependent variable, whereas dose of tranexamic acid and treatment will be included as covariates.

    Time frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)

  2. Re-operation for Bleeding or Tamponade

    Analyzed with a binomial regression

    Time frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)

  3. Duration of ICU Stay

    Analyzed using an ANCOVA model.

    Time frame: Number of hours in ICU are being collected at the Post-Operative Visit. Hour collection will start upon arrival at ICU post surgery and stop at ICU exit, up to 10 days maximum.

  4. MACE (Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke)

    A Cox proportional hazard model will be used to analyze the time to the first occurrence of the composite of death, non-fatal MI, or non-fatal stroke (MACE).

    Time frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)

08

Results

Posted Oct 26, 2026

Participant flow

Participant flow — Overall Study
MilestoneTopical Tranexamic Acid/PlaceboIntravenous Tranexamic Acid/Placebo
Started16241618
Completed16241618
Not completed00

Outcome measures

PrimaryThe Proportion of Patients Experiencing an In-hospital Seizure

To determine in patients undergoing on-pump cardiac surgery, if topical tranexamic acid (intra-pericardial) is superior to the usual intravenous tranexamic acid administration for reducing the risk of in-hospital seizure.

Time frame:
Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
Reported as:
Count of participants · Participants
The Proportion of Patients Experiencing an In-hospital Seizure
ParticipantsTopical Tranexamic Acid/PlaceboIntravenous Tranexamic Acid/Placebo
The Proportion of Patients Experiencing an In-hospital Seizure411
SecondaryThe Proportion of Patients In-hospital Who Receive Red Blood Cell Transfusions

To determine in patients undergoing on-pump cardiac surgery, if topical tranexamic acid (intra-pericardial) compared with intravenous tranexamic acid administration is associated with a non-inferior risk of in-hospital red blood cell transfusion.

Time frame:
Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
Reported as:
Count of participants · Participants
The Proportion of Patients In-hospital Who Receive Red Blood Cell Transfusions
ParticipantsTopical Tranexamic Acid/PlaceboIntravenous Tranexamic Acid/Placebo
The Proportion of Patients In-hospital Who Receive Red Blood Cell Transfusions570433
Other pre-specifiedBlood Product Transfusions

Analyzed using an ANCOVA model. In such a model, bags of blood product will be included as a dependent variable, whereas dose of tranexamic acid and treatment will be included as covariates.

Time frame:
Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
Reported as:
Count of participants · Participants
Blood Product Transfusions
ParticipantsTopical Tranexamic Acid/PlaceboIntravenous Tranexamic Acid/Placebo
Blood Product Transfusions756583
Other pre-specifiedRe-operation for Bleeding or Tamponade

Analyzed with a binomial regression

Time frame:
Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
Reported as:
Count of participants · Participants
Re-operation for Bleeding or Tamponade
ParticipantsTopical Tranexamic Acid/PlaceboIntravenous Tranexamic Acid/Placebo
Re-operation for Bleeding or Tamponade6346
Other pre-specifiedDuration of ICU Stay

Analyzed using an ANCOVA model.

Time frame:
Number of hours in ICU are being collected at the Post-Operative Visit. Hour collection will start upon arrival at ICU post surgery and stop at ICU exit, up to 10 days maximum.
Reported as:
Median · hour
Duration of ICU Stay
hourTopical Tranexamic Acid/PlaceboIntravenous Tranexamic Acid/Placebo
Duration of ICU Stay24 (20 to 47)24 (20 to 46)
Other pre-specifiedMACE (Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke)

A Cox proportional hazard model will be used to analyze the time to the first occurrence of the composite of death, non-fatal MI, or non-fatal stroke (MACE).

Time frame:
Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
Reported as:
Count of participants · Participants
MACE (Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke)
ParticipantsTopical Tranexamic Acid/PlaceboIntravenous Tranexamic Acid/Placebo
MACE (Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke)4031
Post-hocAll Seizures

The proportion of patients experiencing an in-hospital seizure (all).

Time frame:
Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
Reported as:
Count of participants · Participants
All Seizures
ParticipantsTopical Tranexamic Acid/PlaceboIntravenous Tranexamic Acid/Placebo
All Seizures414

Adverse events

Collected over Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)]. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Topical Tranexamic Acid/Placebo12/1,624 (0.7%)0/1,624 (0%)0/1,624 (0%)
Intravenous Tranexamic Acid/Placebo10/1,618 (0.6%)0/1,618 (0%)0/1,618 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Topical Tranexamic Acid/Intravenous PlaceboIntravenous Tranexamic Acid/Topical PlaceboTotal
Mean66.3 ± 8.865.7 ± 9.166 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Topical Tranexamic Acid/Intravenous PlaceboIntravenous Tranexamic Acid/Topical PlaceboTotal
Female375348723
Male124812702518
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Topical Tranexamic Acid/Intravenous PlaceboIntravenous Tranexamic Acid/Topical PlaceboTotal
White153515253060
Asian6264126
Aboriginal or American Indian12820
Other142135
Missing101
Body mass index
Body mass index(kg/m^2)Topical Tranexamic Acid/Intravenous PlaceboIntravenous Tranexamic Acid/Topical PlaceboTotal
Mean28.9 ± 5.128.8 ± 5.028.8 ± 5.1
History of Myocardial Infarction
History of Myocardial Infarction(Participants)Topical Tranexamic Acid/Intravenous PlaceboIntravenous Tranexamic Acid/Topical PlaceboTotal
Count of participants6126491261
History of Diabetes
History of Diabetes(Participants)Topical Tranexamic Acid/Intravenous PlaceboIntravenous Tranexamic Acid/Topical PlaceboTotal
Count of participants486471957
History of Stroke
History of Stroke(Participants)Topical Tranexamic Acid/Intravenous PlaceboIntravenous Tranexamic Acid/Topical PlaceboTotal
Count of participants7364137
History of Seizure
History of Seizure(Participants)Topical Tranexamic Acid/Intravenous PlaceboIntravenous Tranexamic Acid/Topical PlaceboTotal
Count of participants15621

3 further baseline measures are reported on the registry.

09

Study locations

16 sites
  • Kelowna General Hospital
    Kelowna, British Columbia, Canada
  • St. Boniface Hospital
    Winnipeg, Manitoba R2H 2A6, Canada
  • Saint John Regional Hospital
    Saint John, New Brunswick E2L 4L2, Canada
  • Hamilton Health Sciences - General Hospital
    Hamilton, Ontario L8L 2X2, Canada
  • CHUM
    Montreal, Ontario, Canada
  • Montreal Heart Institute
    Montreal, Quebec H1T 1C8, Canada
  • CIUSSS NIM/Hôpital Sacré-Coeur de Montréal
    Montreal, Quebec, Canada
  • IUCPQ
    Québec, Quebec, Canada
  • Beijing Anzhen Hospital
    Beijing, China
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, China
  • Nemocnice Agel Třinec
    Třinec, Czechia
  • University of Malaya
    Kuala Lumpur, Malaysia
  • Auckland City Hospital
    Auckland, New Zealand
  • Petrovsky National Research Centre
    Moscow, Russia
  • E.Meshalkin National Medical Research Center
    Novosibirsk, Russia
  • Saint-Petersburg State University Hospital
    Saint Petersburg, Russia
10

References and documents

Publications

  • Spence J, Long S, Tidy A, Raymer K, Devereaux PJ, Lamy A, Whitlock R, Syed S. Tranexamic Acid Administration During On-Pump Cardiac Surgery: A Survey of Current Practices Among Canadian Anesthetists Working in Academic Centers. Anesth Analg. 2017 Dec;125(6):1863-1870. doi: 10.1213/ANE.0000000000002422. PubMed 28858904 ↗
  • Lamy A, Tong W, Gao P, Chrolavicius S, Gafni A, Yusuf S, Connolly SJ. The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial. Can J Cardiol. 2012 Jan-Feb;28(1):95-101. doi: 10.1016/j.cjca.2011.08.112. Epub 2011 Oct 8. PubMed 21983111 ↗
  • Habbab LM, Hussain S, Power P, Bashir S, Gao P, Semelhago L, VanHelder T, Parry D, Chu V, Lamy A. Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) study: Results of a pilot study. J Card Surg. 2019 May;34(5):305-311. doi: 10.1111/jocs.14027. Epub 2019 Mar 25. PubMed 30908754 ↗
  • Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, Bussieres JS, McGuinness S, Byrne K, Chan MT, Landoni G, Wallace S; ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med. 2017 Jan 12;376(2):136-148. doi: 10.1056/NEJMoa1606424. Epub 2016 Oct 23. PubMed 27774838 ↗
  • Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussieres JS, Cote D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008 May 29;358(22):2319-31. doi: 10.1056/NEJMoa0802395. Epub 2008 May 14. PubMed 18480196 ↗
  • Mazer CD, Whitlock RP, Fergusson DA, Belley-Cote E, Connolly K, Khanykin B, Gregory AJ, de Medicis E, Carrier FM, McGuinness S, Young PJ, Byrne K, Villar JC, Royse A, Grocott HP, Seeberger MD, Mehta C, Lellouche F, Hare GMT, Painter TW, Fremes S, Syed S, Bagshaw SM, Hwang NC, Royse C, Hall J, Dai D, Mistry N, Thorpe K, Verma S, Juni P, Shehata N; TRICS Investigators and Perioperative Anesthesia Clinical Trials Group. Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery. N Engl J Med. 2018 Sep 27;379(13):1224-1233. doi: 10.1056/NEJMoa1808561. Epub 2018 Aug 26. PubMed 30146969 ↗
  • Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F. High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Ann Thorac Surg. 2012 Jan;93(1):148-54. doi: 10.1016/j.athoracsur.2011.07.085. Epub 2011 Nov 4. PubMed 22054656 ↗
  • Lamy A, Sirota DA, Jacques F, Poostizadeh A, Noiseux N, Efremov S, Demers P, Akselrod B, Wang CY, Arora RC, Branny P, McGuinness SP, Brown CD, Jeanmart H, Zhao Q, Zhang H, Belley-Cote EP, Whitlock RP, Browne A, Copland I, Vincent J, Khatun R, Balasubramanian K, Bangdiwala SI, McGillion MH, Fox-Robichaud AE, Spence J, Yusuf S, Devereaux PJ; DEPOSITION Study Group. Topical Versus Intravenous Tranexamic Acid in Patients Undergoing Cardiac Surgery: The DEPOSITION Randomized Controlled Trial. Circulation. 2024 Oct 22;150(17):1315-1323. doi: 10.1161/CIRCULATIONAHA.124.069606. Epub 2024 Apr 8. PubMed 38587333 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Nov 2023, 50 months.

Results were first posted in Oct 2026, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2019
First posted
May 17, 2019
StartActual
Sep 17, 2019
Primary completionActual
Nov 28, 2023
CompletionActual
Nov 28, 2023
Results first posted
Oct 26, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 26, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (1 Canada, 1 Russia)
  • IUCPQ · Québec, Canada
  • Saint-Petersburg State University Hospital · Saint Petersburg, Russia
Show 2 removed
  • IUCPQ · Quebec City, Canada
  • Saint-Petersburg State University Hospital · Saint-Petersburg, Russian Federation
Oct 26, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedThe proportionProportion of patients experiencingPatients Experiencing an inIn-hospital seizureSeizureTime frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
Oct 26, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38587333 ↗
Oct 26, 2026
Secondary outcomes
5 edited
What changed in the outcomes
  • EditedThe proportionProportion of patients inPatients In-hospital who receive red blood cell transfusionsWho Receive Red Blood Cell TransfusionsTime frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
  • Editedother outcomeBlood product transfusionsProduct TransfusionsTime frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
  • Editedother outcomeRe-operation for bleedingBleeding or tamponadeTamponadeTime frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
  • Editedother outcomeDuration of ICU stayStayTime frame: Number of hours in ICU are being collected at the Post-Operative Visit. Hour collection will start upon arrival at ICU post surgery and stop at ICU exit, up to 10 days maximum.
  • Editedother outcomeMACE (Death, nonNon-fatal Myocardial Infarction (MI), or nonNon-fatal strokeStroke)Time frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38587333 ↗
    2 sites added, 2 sites removed
    Show 2 added (1 Canada, 1 Russia)
    • IUCPQ · Québec, Canada
    • Saint-Petersburg State University Hospital · Saint Petersburg, Russia
    Show 2 removed
    • IUCPQ · Quebec City, Canada
    • Saint-Petersburg State University Hospital · Saint-Petersburg, Russian Federation
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedThe proportionProportion of patients experiencingPatients Experiencing an inIn-hospital seizureSeizureTime frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
    Secondary outcomes 5 edited
    What changed in the outcomes
    • EditedThe proportionProportion of patients inPatients In-hospital who receive red blood cell transfusionsWho Receive Red Blood Cell TransfusionsTime frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
    • Editedother outcomeBlood product transfusionsProduct TransfusionsTime frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
    • Editedother outcomeRe-operation for bleedingBleeding or tamponadeTamponadeTime frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
    • Editedother outcomeDuration of ICU stayStayTime frame: Number of hours in ICU are being collected at the Post-Operative Visit. Hour collection will start upon arrival at ICU post surgery and stop at ICU exit, up to 10 days maximum.
    • Editedother outcomeMACE (Death, nonNon-fatal Myocardial Infarction (MI), or nonNon-fatal strokeStroke)Time frame: Start of surgery to hospital discharge or 10 days maximum (whichever occurs first)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT03954314
Responsible party
Sponsor
First posted
May 17, 2019
Start date
Sep 17, 2019
Primary completion
Nov 28, 2023
Completion
Nov 28, 2023
Results posted
Oct 26, 2026
Last update
Oct 26, 2026

Study contacts

Andre Lamy, MD
principal investigator · Population Health Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion